Key Takeaways
- • Toscafund-backed consortium Tulip UK agrees to acquire Spire Healthcare for £1.03bn, taking the UK hospital operator private at 250p per share—a 66% premium to the May 13 closing price before deal talks were disclosed.
- • Acquisition consortium comprises Toscafund Asset Management (already Spire's second-largest shareholder), THCP Advisory, and Ares Management, with Toscafund leading the transaction after months of strategic discussions.
- • Spire operates 38 hospitals and approximately 55 clinics across England, Wales, and Scotland, serving over 1,400 employers through private GP practices and occupational health services, representing a substantial private healthcare platform.
- • Post-acquisition, Tulip UK will conduct a 12-month strategic review that may result in disposal of portions of Spire's private GP business and workforce reductions, signaling potential operational restructuring.
- • Transaction removes Spire from public markets amid sector-wide headwinds including cost inflation and weak investor sentiment in UK-listed healthcare, providing the consortium with flexibility for longer-term value creation strategy.
Summary
Toscafund Asset Management has agreed to take UK hospital operator Spire Healthcare private through a consortium vehicle, Tulip UK, in a deal valuing the company at approximately £1.03bn. The acquisition, which includes co-investors THCP Advisory and Ares Management, represents a significant consolidation of the UK's private healthcare sector and marks an exit from public markets for a company facing mounting sectoral pressures.
Under the transaction terms, Spire shareholders will receive 250p per share, representing a 66% premium to the company's closing price on May 13—the day before the deal negotiations were publicly disclosed. Toscafund, which already held Spire's second-largest shareholder position, had been negotiating the potential transaction for several months prior to announcement. The consortium structure reflects a collaboration among established alternative asset managers seeking to capitalize on a mispriced healthcare asset during a period of subdued equity market sentiment.
Spire's operational footprint is substantial within the UK private healthcare landscape. The company operates 38 hospitals and approximately 55 clinics across England, Wales, and Scotland, alongside private GP practices and occupational health services serving over 1,400 employers. This diversified service offering positions the platform as a meaningful consolidator in the fragmented UK private healthcare market.
The acquisition occurs against the backdrop of Spire's ongoing strategic review, which commenced in September 2025. Following completion of the takeover, Tulip UK intends to conduct its own 12-month strategic review, which may include reassessment of Spire's primary care operations. This post-acquisition assessment could result in selective divestitures of portions of the private GP business and associated workforce optimization, signaling that the consortium anticipates operational restructuring opportunities within the platform.
For Toscafund and its consortium partners, the transaction enables pursuit of a longer-term investment strategy unconstrained by public market pressures. The timing reflects both the attractive entry valuation and the broader challenge facing UK-listed healthcare operators navigating sustained cost inflation and investor capital rotation away from the sector.
Under the transaction terms, Spire shareholders will receive 250p per share, representing a 66% premium to the company's closing price on May 13—the day before the deal negotiations were publicly disclosed. Toscafund, which already held Spire's second-largest shareholder position, had been negotiating the potential transaction for several months prior to announcement. The consortium structure reflects a collaboration among established alternative asset managers seeking to capitalize on a mispriced healthcare asset during a period of subdued equity market sentiment.
Spire's operational footprint is substantial within the UK private healthcare landscape. The company operates 38 hospitals and approximately 55 clinics across England, Wales, and Scotland, alongside private GP practices and occupational health services serving over 1,400 employers. This diversified service offering positions the platform as a meaningful consolidator in the fragmented UK private healthcare market.
The acquisition occurs against the backdrop of Spire's ongoing strategic review, which commenced in September 2025. Following completion of the takeover, Tulip UK intends to conduct its own 12-month strategic review, which may include reassessment of Spire's primary care operations. This post-acquisition assessment could result in selective divestitures of portions of the private GP business and associated workforce optimization, signaling that the consortium anticipates operational restructuring opportunities within the platform.
For Toscafund and its consortium partners, the transaction enables pursuit of a longer-term investment strategy unconstrained by public market pressures. The timing reflects both the attractive entry valuation and the broader challenge facing UK-listed healthcare operators navigating sustained cost inflation and investor capital rotation away from the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.